In a prospective study of patients with leishmaniasis diagnosed at the San Camilo of Pozuzo Health Center, we compared two treatments: glucantime 20 mg Base/kg/day IM for 20 days, with a maximum dose of 1275 mg/day (treatment performed from January 1999 to December 2000), versus sodium stibogluconate 20 mg Base/kg/day IM for 30 days, with a maximum dose of 1500 mg/day (treatment performed from January to December 2001). Of the 173 leishmaniasis patients, 116 had L. cutanea (67.05%) and 57 had L. cutaneomucosa (32.95%). Of the 135 patients treated with glucantime (78.03%) and 38 with sodium stibogluconate (21.96%), 45 (33.3%) and 25 (67.78%) respectively, presented adverse reactions. Six patients under treatment with glucantime (4.44%) and 4 treated with sodium stibogluconate (10.53%) discontinued treatment. Fifteen patients under glucantime (10 affected with L. Cutaneomucosa and 5 with L...